Patent · US Active

Treatment for rheumatoid arthritis

US10913792B2 · kind B2 · utility

0Cited by

2References

7Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Stefan Härtle · Jesenwang, DE
Stephane Leclair · Gauting, DE
Amgad Shebl · Planegg, DE
Stefan Steidl · Munich, DE
Bodo BROCKS · Gilching, DE
Daniela Della DUCATA · Planegg, DE
Kai Rosport · Planegg, DE

Key dates

Filing date	Jan 26, 2018
Grant date	Feb 9, 2021
Priority date	—
Expiry date	Jan 26, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.